Extract of Pelargonium sidoides (EPs® 7630) inhibits the interactions of group A-streptococci and host epithelia in vitro

Conrad, Andreas; Jung, Irina; Tioua, Diane; Lallemand, Caroline; Carrapatoso, Felipe; Engels, I.; Daschner, Franz; Frank, Uwe

doi:10.1016/j.phymed.2006.11.018

Cited by 60 publications

(54 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The inhibition of the streptococcal invasion of epithelial cells protects the host from microorganisms that evade host defenses and antibiotic treatment, thus preventing recurrent infections. By these means, its mode of action is entirely different from that of classical antibiotics (10). As EPs 7630 does not interfere with bacterial life cycle and metabolism, development of bacterial resistance does not occur.…”

Section: Discussionmentioning

confidence: 98%

“…This finding could be based on the particular mode of action in EPs 7630, which comprises of antiviral (6-8), antibacterial (9) and immune modulating effects (9)(10)(11). The inhibition of the streptococcal invasion of epithelial cells protects the host from microorganisms that evade host defenses and antibiotic treatment, thus preventing recurrent infections.…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, EPs 7630 (EPs ® 7630 is the active ingredient of the product Umckaloabo ® (ISO-Arzneimittel, Ettlingen, Germany)), a herbal drug preparation from the roots of Pelargonium sidoides, has been shown to exhibit antiviral (6)(7)(8), antibacterial (9) as well as modulating and stimulating effects on the non-specific immune system (9)(10)(11), which are based on inhibition of bacterial adhesion to host cells (10), improved phagocytosis and intracellular killing of microbes (11), increased mucociliary clearance (12), interferon-like action (9,13) and enhancing effects on the production of cytokines (9). The latter two are especially essential for activation of innate defense mechanisms against infections (9,14).…”

Section: Introductionmentioning

confidence: 99%

“…The latter two are especially essential for activation of innate defense mechanisms against infections (9,14). resistance (10), nor could there be found any indication of risk to develop resistance in viruses (8).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Clinical Efficacy and Safety of Liquid Pelargonium sidoides Preparation (EPs 7630) in Children with Acute Non-Streptococcal Tonsillopharyngitis

Бережной

Heger

Lehmacher³

et al. 2016

J Compr Ped

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Clinical Efficacy and Safety of Liquid Pelargonium sidoides Preparation (EPs 7630) in Children with Acute Non-Streptococcal Tonsillopharyngitis

Бережной

Heger

Lehmacher³

et al. 2016

J Compr Ped

View full text Add to dashboard Cite

show abstract

“…Several authors (Alonso, 2004;Mativandlela et al, 2006;Conrad et al, 2007;Matthys, Heger, 2007b;Kolodziej, Kiderlen, 2007a), report that the roots of P. sidoides have antimicrobial activity, inhibiting Gram-positive germs (Staphylococcus aureus, Streptococcus pneumoniae, S. beta-hemolitico 1451), Gram-negative germs (Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis), virus (Haemophilus influenzae, Moraxella catarrhalis), and fungus (Aspergillus niger, Fusarium oxysporum, Rhizopus stolonifer). Among the components that make this activity possible are the coumarins (Alonso, 2004).…”

Section: Pharmacological Activitiesmentioning

confidence: 99%

Evaluation of medicine package inserts: a study of two cases of Pelargonium sidoides D.C. phytomedicines

Linhares

Oliveira

Silva

2010

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

In order for a phytotherapeutic drug be approved and sold in Brazil, it must be registered with the National Sanitary Surveillance Agency (ANVISA), where the quality, safety and efficacy of the product are carefully appraised. In addition, the drug must also meet a number of criteria one of which is the adequacy of the package inserts. Therefore, the aim of this study was to appraise the package inserts of all phytotherapeutic drugs produced using a standardized extract of Pelargonium sidoides, which were registered and available from Brazilian pharmacies. This checking was to ascertain whether these inserts fulfilled the requirements stipulated by RDC 140/03. The information required under RDC 140/03 was appraised through a previously devised standard form. Evaluation of the package inserts revealed that neither of the two brands fully met the requirements of the legislation. Manufacturer 'A' met only 37.0% of the requirements satisfactorily, while 16.0% of the information was considered unsatisfactory and 47.0% of the information was absent. Regarding manufacturer 'B', 64.2% of the analyzed requirements were considered satisfactory, while 16.0% were considered unsatisfactory and 19.8% of the information was absent. A package insert should contain information about medicine for consumers, pharmacists and doctors. However, the results obtained in this study showed that the information presented in the package insert of both medicines was unsatisfactory, and in many cases, violates the legislation.Uniterms: Medicines/formulation of package inserts. Phytotherapeutic drugs. Package inserts/evaluation. Pelargonium sidoides.Para que um medicamento fitoterápico seja comercializado no Brasil, este deve ser registrado junto à ANVISA, onde são avaliados todos os aspectos referentes à qualidade, segurança e eficácia do produto, além de verificar se estes atendem alguns requisitos, sendo um deles a adequação da bula. Por esta razão, neste estudo foram avaliadas as bulas de todos os fitoterápicos elaborados à base do extrato padronizado de Pelargonium sidoides, registrados e disponíveis no mercado brasileiro, com o intuito de verificar se estas atendem aos requisitos exigidos pela RDC 140/03. No presente trabalho, as informações exigidas pela RDC 140/03 foram avaliadas através de um formulário padrão previamente elaborado. Após avaliação das bulas pode ser verificado que nenhuma das duas marcas atendia por completo as exigências da legislação, sendo que o fabricante "A" atendeu apenas 37,0% dos requisitos exigidos de forma satisfatória, enquanto 16,0% das informações foram consideradas insatisfatórias e em 47,0% as informações estavam ausentes. Com relação ao fabricante "B", 64,2% dos itens analisados foram considerados satisfatórios, enquanto 16,0% foram considerados insatisfatório e em 19,8% as informações estavam ausentes. A bula deveria conter informações sobre o medicamento para consumidores, farmacêuticos e médicos, no entanto, os resultados obtidos neste estudo mostram que as informações apresentadas nas bulas foram ...

show abstract

Pelargonium sidoides extract for acute respiratory tract infections

Timmer

Günther²,

Rücker³

et al. 2008

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

Extract of Pelargonium sidoides (EPs® 7630) inhibits the interactions of group A-streptococci and host epithelia in vitro

Cited by 60 publications

References 20 publications

Clinical Efficacy and Safety of Liquid Pelargonium sidoides Preparation (EPs 7630) in Children with Acute Non-Streptococcal Tonsillopharyngitis

Clinical Efficacy and Safety of Liquid Pelargonium sidoides Preparation (EPs 7630) in Children with Acute Non-Streptococcal Tonsillopharyngitis

Evaluation of medicine package inserts: a study of two cases of Pelargonium sidoides D.C. phytomedicines

Pelargonium sidoides extract for acute respiratory tract infections

Contact Info

Product

Resources

About